Algiax Pharmaceuticals GmbH

www.algiax.com

Algiax Pharmaceuticals is a clinical-stage biotechnology company with its lead candidate AP-325 - a small-molecule GABAA receptor modulator - in clinical phase II

About us

Algiax Pharmaceuticals is a clinical-stage biotechnology company established in 2011. It is dedicated to the discovery and development of innovative products to treat diseases with a high unmet medical need.

Algiax’ lead candidate AP-325 is a small-molecule GABAA receptor modulator in clinical development as a therapy for neuropathic pain. A Phase IIa multi-center proof-of-concept study evaluating AP-325 in chronic neuropathic pain is currently running and expected to deliver first results by end of 2021.

GABAA is a major inhibitory neurotransmitter in the central nervous system. AP-325 is designed to treat a large group of neuropathic pain patients and does not penetrate the brain as such there are no sedative actions that limit their use.

Consequently, AP-325 as a non-opioid has a significantly lower potential for addiction or abuse and is truly unique because it is non-sedative, not centrally active and has a long-lasting efficacy.

Address
Algiax Pharmaceuticals GmbH
Max-Planck-Str. 15a
Erkrath
Germany

Phone: +49 211 6178510
Internet: www.algiax.com

Products and services

Algiax Pharmaceuticals is looking for potential partners for its lead candidate AP-325 in chronic neuropathic pain.

Click here if you notice an image that violates copyright or privacy rights.

Get in contact
OK

We only use functionally necessary cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection